Answers are grounded in this paper and cite their sources.
Findings identify TIGIT as an immunotherapeutic target in PDAC, suggesting dual blockade may enhance treatment.
Our findings identify TIGIT as a promising immunotherapeutic target in PDAC and suggest that dual checkpoint blockade (TIGIT/PD-1), alongside restoration of DNAM-1 signaling, may overcome immune suppression. These results provide mechanistic rationale to inform future clinical trials in PDAC.
No takes yet. Share an insight, caveat, or question.
Quatannens et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: